NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis → Boost your retirement with these AI payouts (From InvestorPlace) (Ad) Free NKTX Stock Alerts $6.56 -0.17 (-2.53%) (As of 11:28 AM ET) Add Compare Share Share Today's Range$6.53▼$6.7450-Day Range$6.25▼$13.1052-Week Range$1.28▼$16.24Volume67,111 shsAverage Volume1.69 million shsMarket Capitalization$324.20 millionP/E RatioN/ADividend YieldN/APrice Target$17.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nkarta alerts: Email Address Nkarta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside171.8% Upside$17.83 Price TargetShort InterestBearish14.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 3 Articles This WeekInsider TradingAcquiring Shares$20 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.27) to ($2.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector438th out of 918 stocksPharmaceutical Preparations Industry195th out of 418 stocks 4.5 Analyst's Opinion Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNkarta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nkarta's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.02% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Nkarta has recently increased by 24.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NKTX. Previous Next 1.7 News and Social Media Coverage News SentimentNkarta has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nkarta this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nkarta are expected to decrease in the coming year, from ($2.27) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. About Nkarta Stock (NASDAQ:NKTX)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More NKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTX Stock News HeadlinesMay 18 at 11:27 PM | morningstar.comNkarta Inc Ordinary SharesMay 15, 2024 | americanbankingnews.comNkarta (NASDAQ:NKTX) Price Target Lowered to $13.00 at Needham & Company LLCMay 15, 2024 | americanbankingnews.comNkarta (NASDAQ:NKTX) Price Target Raised to $23.00 at HC WainwrightMay 12, 2024 | americanbankingnews.comNkarta (NASDAQ:NKTX) PT Lowered to $15.00May 10, 2024 | finance.yahoo.comNkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational AnalysisMay 10, 2024 | finanznachrichten.deNkarta, Inc.: Nkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 10, 2024 | markets.businessinsider.comNkarta Inc. Buy Rating Affirmed Amidst Promising Clinical Studies and Robust Financial HealthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Nkarta’s NKX019 Shows Promise in Lupus Nephritis Clinical TrialsMay 10, 2024 | investorplace.comNKTX Stock Earnings: Nkarta Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 9, 2024 | globenewswire.comNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 7, 2024 | investorplace.comOpportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's RadarApril 27, 2024 | msn.comAmgen’s Blincyto data send Cullinan higherApril 27, 2024 | seekingalpha.comNkarta: Down 50% Since March With A Clinical Catalyst AheadApril 18, 2024 | finance.yahoo.comNkarta, Inc. (NKTX) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)April 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)April 8, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 3, 2024 | globenewswire.comNkarta to Participate in Upcoming Investor ConferencesMarch 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 27, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)March 27, 2024 | msn.comPromising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-HeartedMarch 26, 2024 | sg.finance.yahoo.comNkarta, Inc. (NKTX) interactive stock chart – Yahoo FinanceSee More Headlines Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/21/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$17.83 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+165.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.13% Return on Assets-25.96% Debt Debt-to-Equity RatioN/A Current Ratio19.95 Quick Ratio19.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book1.21Miscellaneous Outstanding Shares49,420,000Free Float46,649,000Market Cap$332.60 million OptionableOptionable Beta0.88 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Paul J. Hastings (Age 64)CEO, President & Director Comp: $938.41kDr. Alicia J. Hager (Age 54)Chief Legal Officer & Corporate Secretary Comp: $590.94kMs. Alyssa Levin C.A. (Age 39)CPA, Chief Financial & Business Officer and Principal Accounting Officer Dr. Ralph Brandenberger Ph.D. (Age 55)Chief Technical Officer Dr. James Trager Ph.D. (Age 61)Chief Scientific Officer Mr. Greg MannVice President of Public Affairs and Investor RelationsDr. David R. Shook M.D. (Age 46)Chief Medical Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRKamadaNASDAQ:KMDASilverback TherapeuticsNASDAQ:SBTXErascaNASDAQ:ERASADC TherapeuticsNYSE:ADCTView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 3,000,000 shares on 5/17/2024Ownership: 21.864%Janus Henderson Group PLCBought 838,839 shares on 5/16/2024Ownership: 1.697%California State Teachers Retirement SystemSold 1,937 shares on 5/16/2024Ownership: 0.006%Lazard Asset Management LLCSold 2,225 shares on 5/15/2024Ownership: 0.009%SR One Capital Management LPBought 2,000,000 shares on 5/14/2024Ownership: 6.745%View All Insider TransactionsView All Institutional Transactions NKTX Stock Analysis - Frequently Asked Questions Should I buy or sell Nkarta stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares. View NKTX analyst ratings or view top-rated stocks. What is Nkarta's stock price target for 2024? 5 brokerages have issued twelve-month price targets for Nkarta's shares. Their NKTX share price targets range from $13.00 to $25.00. On average, they predict the company's share price to reach $17.83 in the next twelve months. This suggests a possible upside of 171.8% from the stock's current price. View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts. How have NKTX shares performed in 2024? Nkarta's stock was trading at $6.60 at the beginning of 2024. Since then, NKTX stock has decreased by 0.6% and is now trading at $6.56. View the best growth stocks for 2024 here. When is Nkarta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our NKTX earnings forecast. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) released its earnings results on Thursday, March, 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.05. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG). When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. Who are Nkarta's major shareholders? Nkarta's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (21.86%), SR One Capital Management LP (6.74%), Vanguard Group Inc. (3.98%), Wasatch Advisors LP (2.36%), Janus Henderson Group PLC (1.70%) and Susquehanna Fundamental Investments LLC (0.15%). Insiders that own company stock include David Shook, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NKTX) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Crypto for AIWeiss RatingsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.